ADTX
ADITXT INC
Latest price
As of Nov 6, 2026, 10:06 AM EST · Market data by Massive
Market cap
—
Volume
911.8K
Previous close
$0.0001
Day range
$0.0004 – $0.0005
Listed
—
Coverage
9 articles
Price performance
Recent trading
Newsroom
Latest ADTX coverage
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
[ad_1] · $12.5M in combined January 2021 and February 2021 sales · President Biden signs American Recovery Act into law Rehovot, Israel – (NewMediaWire) – March 12, 2021 – Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and im
NewMediaWire | Immunologist and Clinical Transplant Expert, Dolly B. Tyan, PhD, Joins Aditxt as Senior VP of Clinical Development
[ad_1] Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program Mountain View, CA – (NewMediaWire) – January 29, 2021 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company developing biotechnologies specifically focused on improving the health of the immune system through immune mon
Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore
[ad_1] Voorhies hasExtensive Business and Industry Experience in Diagnostics & Monitoring Mountain View, CA – (NewMediaWire) – November 20, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through im
Former Chief Medical Officer and Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security, Dr. Jeffrey Runge, Appointed to Aditxt Board of Directors
[ad_1] Dr. Runge brings 35 years’ experience as an Emergency Medicine Physician, Federal Government Executive and Public Policy Strategist Mountain View, CA – (NewMediaWire) – October 01, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improv
Aditxt Announces First AditxtEngage Event, Continuing Series of Investor Opportunities to Engage with Company
[ad_1] First AditxtEngage™ Event with Amro Albanna, CEO, to be held on Tuesday, October 6th at 4:30pm ET Mountain View, CA – (NewMediaWire) – October 02, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune syste
Aditx Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
[ad_1] Virtual Presentation on Wednesday, September 16th at 3:00 PM EDT Loma Linda, CA – (NewMediaWire) – September 10, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and&#
Aditxt Signs Collaboration Agreement with Salveo Diagnostics to Commercialize AditxtScore Platform Starting in Q4, 2020
[ad_1] LOMA LINDA, CA – (NewMediaWire) – September 03, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has signed a Collaboration Agreement with
Aditx Therapeutics Announces Pricing of $9.6 Million Follow-On Public Offering
[ad_1] LOMA LINDA, CA – (NewMediaWire) – September 02, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the pricing of an underwritten publi
Former President of the Global Business Unit at Schering AG, Dr. Joachim-Friedrich Kapp, MD, PhD, to Lead Aditx Therapeutics Clinical Development, Autoimmunity
[ad_1] 30 Year Industry Veteran with FDA and EMA Experience will Assume Newly Created Executive Role Loma Linda, CA – (NewMediaWire) – August 14, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system throug